Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2018

January 2018 | 42 pages | ID: M9A67FD4951EN
Global Markets Direct

Abstracts

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2018, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape.

Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys, lung, nerves, skin and joints. Symptoms include shortness of breath or cough, fever, loss of appetite, rashes, muscle and/or joint pain. Treatment includes immunosuppressive medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Unknown stages are 1, 3 and 1 respectively.

Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Microscopic Polyangiitis (MPA) - Overview
Microscopic Polyangiitis (MPA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Microscopic Polyangiitis (MPA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
Celltrion Inc
ChemoCentryx Inc
Sandoz International GmbH
Teijin Pharma Ltd
TTY Biopharm Company Ltd
Microscopic Polyangiitis (MPA) - Drug Profiles
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Microscopic Polyangiitis (MPA) - Dormant Projects
Microscopic Polyangiitis (MPA) - Product Development Milestones
Featured News & Press Releases
Jun 19, 2017: Sandoz receives approval in Europe for Rixathon (biosimilar rituximab) to treat blood cancers and immunological diseases
May 18, 2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab)
Apr 21, 2017: Sandoz Receives CHMP Positive Opinion For Rixathon (rituximab)
Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Microscopic Polyangiitis (MPA) - Pipeline by Celltrion Inc, H1 2018
Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H1 2018
Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H1 2018
Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H1 2018
Microscopic Polyangiitis (MPA) - Pipeline by TTY Biopharm Company Ltd, H1 2018
Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Celltrion Inc
ChemoCentryx Inc
Sandoz International GmbH
Teijin Pharma Ltd
TTY Biopharm Company Ltd